Thorsten Fuereder
Medical University of Vienna(AT)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Brain Metastases and Treatment, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,089 cited
- → Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study(2022)450 cited
- → Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial(2022)379 cited
- → Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy(2020)217 cited
- → Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial(2024)181 cited
- → Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer(2025)177 cited
- → Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis(2010)170 cited
- → Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation(2007)153 cited
- → KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)(2018)135 cited
- → Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2019)131 cited